Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Assets (2016 - 2025)

China Pharma Holdings' Assets history spans 16 years, with the latest figure at $31.0 million for Q4 2025.

  • For Q4 2025, Assets rose 108.22% year-over-year to $31.0 million; the TTM value through Dec 2025 reached $31.0 million, up 108.22%, while the annual FY2025 figure was $31.0 million, 108.22% up from the prior year.
  • Assets reached $31.0 million in Q4 2025 per CPHI's latest filing, up from $15.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $31.0 million in Q4 2025 to a low of $13.5 million in Q3 2024.
  • Average Assets over 5 years is $17.6 million, with a median of $16.3 million recorded in 2022.
  • Peak YoY movement for Assets: dropped 21.48% in 2022, then surged 108.22% in 2025.
  • A 5-year view of Assets shows it stood at $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then dropped by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then surged by 108.22% to $31.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Assets are $31.0 million (Q4 2025), $15.8 million (Q3 2025), and $13.8 million (Q2 2025).